The single rule of peptide stacking: combine compounds with different, complementary mechanisms — never two that hit the same receptor. Below, every common research combination is rated 🟢 Synergistic, 🟡 Neutral/redundant, or 🔴 Avoid, with the reasoning. For laboratory research use only — not medical advice.
| Stack / Combination | Category | Verdict | Why (mechanism) |
|---|---|---|---|
| BPC-157 + TB-500 ("Wolverine") | Healing / Recovery | Synergistic | Complementary repair — BPC-157 drives local angiogenesis and structural tissue repair; TB-500 promotes systemic cell migration and reduces fibrosis. Non-overlapping. |
| CJC-1295 (no DAC) + Ipamorelin | Growth Hormone | Synergistic | GHRH analog + selective GHRP produce greater pulsatile GH release than either alone. The 'gold standard' GH pairing. |
| Tesamorelin + Ipamorelin | Growth Hormone | Synergistic | Same GHRH + GHRP logic; sold pre-made as a TESA/IPA blend by some vendors. |
| BPC-157 + TB-500 + GHK-Cu (GLOW) | Healing / Skin | Synergistic | Adds copper-peptide GHK-Cu (ECM/collagen remodeling) to the healing pair — three distinct repair mechanisms. |
| + KPV (KLOW blend) | Healing / Anti-inflammatory | Synergistic | Adds KPV (an α-MSH fragment) for anti-inflammatory / melanocortin action — four non-overlapping mechanisms. |
| Semaglutide + Cagrilintide (CagriSema) | Metabolic | Synergistic | GLP-1 + amylin analog engage two independent appetite pathways (~20% in REDEFINE 1). |
| Tirzepatide + Cagrilintide | Metabolic | Synergistic | Dual incretin agonist + amylin analog — complementary appetite mechanisms. |
| Semax + Selank | Cognitive / Nootropic | Synergistic | Different targets — Semax (BDNF/dopaminergic focus) + Selank (anxiolytic, GABA-modulating). |
| CJC-1295 + Ipamorelin + BPC-157 + TB-500 | Recovery | Synergistic | GH stack + healing stack; four non-overlapping mechanisms. Common advanced recovery combo. |
| GHK-Cu + BPC-157 | Skin / Wound | Synergistic | Copper-peptide ECM remodeling + BPC-157 angiogenesis and tissue repair. |
| Ipamorelin + GHRP-2 / GHRP-6 | Growth Hormone | Neutral | Two GHRPs hit the SAME ghrelin receptor — overlapping, diminishing returns. Pair a GHRP with a GHRH instead. |
| CJC-1295 (DAC) + CJC-1295 (no DAC) | Growth Hormone | Neutral | Both GHRH analogs — redundant. Choose one (DAC = steadier; no-DAC = more pulsatile). |
| NAD+ (adjunct) | Longevity / Energy | Neutral | Compatible with the stacks above and used adjunctively, but not a true synergy. |
| Two GLP-1 agonists together | Metabolic | Avoid | Redundant, overlapping incretin mechanism — no added benefit and additive GI side-effects. Use one agonist. |
| Tesofensine + GLP-1 / stimulant | Metabolic / CNS | Avoid | Tesofensine adds adrenergic drive → additive cardiovascular (↑HR/BP) and CNS (insomnia, anxiety) risk. No human safety data for the combo. |
| Retatrutide + Tesofensine | Metabolic / CNS | Avoid | Triple agonist + stimulant: compounded cardiovascular and CNS load, no combination safety data. |
| Melanotan II + appetite stack | Pigmentation | Avoid | MT-II adds nausea, flushing and cardiovascular effects; research-only, limited data. |
| Stacking 3+ GH secretagogues | Growth Hormone | Avoid | Overlapping receptor action raises side-effect load without proportional GH benefit. Keep to one GHRH + one GHRP. |
The strongest pairs combine non-overlapping pathways: BPC-157 + TB-500 (local repair + systemic migration/anti-fibrosis) and CJC-1295 + Ipamorelin (GHRH + GHRP for greater pulsatile GH). Blends like GLOW and KLOW extend the healing pair with GHK-Cu and KPV. On the metabolic side, CagriSema pairs a GLP-1 with an amylin analog for two independent appetite pathways.
Two GHRPs (Ipamorelin + GHRP-2), or DAC and no-DAC CJC-1295 together, overlap on the same receptor — you pay twice for one effect. Pair across classes instead.
Two GLP-1 agonists together (e.g. Semaglutide + Tirzepatide) is the classic mistake — redundant mechanism, additive nausea/GI, no extra benefit. And Tesofensine + a GLP-1 stacks adrenergic stimulation on top of appetite suppression, raising cardiovascular and CNS risk with no combination safety data.
Every compound above is tracked on PepsTracker across 26 vendors, normalized to cost-per-milligram with discount codes applied. Pre-made blends (GLOW, KLOW, TESA/IPA, Sema/Cagri) are available from vendors like Platinum Peptides at 15% off with code pepstracker15 — compare the blend against buying components separately.
The best-supported synergistic pairs combine different mechanisms: BPC-157 + TB-500 for healing, CJC-1295 + Ipamorelin for growth hormone, and GLP-1 + Cagrilintide (CagriSema) for metabolic research. Blends like GLOW and KLOW extend the healing pair.
Avoid stacking two compounds that share a mechanism — two GLP-1 agonists (e.g. Semaglutide + Tirzepatide) or two GHRPs — which add side-effects without benefit. Also avoid stimulant combinations like Tesofensine + a GLP-1, which raise cardiovascular and CNS risk with no combination safety data.
Yes — that four-part "Wolverine" combination (BPC-157 + TB-500 + CJC-1295 + Ipamorelin) pairs a healing stack with a growth-hormone stack across entirely separate mechanisms, which is why it's a common advanced recovery approach in research.